The real-life efficacy and safety of secukinumab therapy (150 and 300 mg) in patients with moderate-to-severe plaque psoriasis: A twelve week, single center, retrospective study
Background and Design: Secukinumab is an effective treatment option in moderate-to-severe plaque type psoriasis. However, there are a few real-life data studies comparing the efficacy of 150 mg and 300 mg dosages. The aim of this study was to evaluate the efficacy and safety of secukinumab at 150 mg...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | |
| Опубликовано: |
Galenos Publishing House,
2021-09-01T00:00:00Z.
|
| Предметы: | |
| Online-ссылка: | Connect to this object online. |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Internet
Connect to this object online.3rd Floor Main Library
| Шифр: |
A1234.567 |
|---|---|
| Копировать 1 | Доступно |